Cargando…

Rituximab use in late antibody-mediated rejection

Detalles Bibliográficos
Autor principal:	Bansal, S. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015506/ https://www.ncbi.nlm.nih.gov/pubmed/27795622 http://dx.doi.org/10.4103/0971-4065.179305

Ejemplares similares

Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation
por: Parajuli, Sandesh, et al.
Publicado: (2017)

Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience
por: Surendra, M., et al.
Publicado: (2016)

A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection
por: Hychko, G., et al.
Publicado: (2011)

Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection
por: Piñeiro, Gastón J, et al.
Publicado: (2018)

The therapeutic challenge of late antibody‐mediated kidney allograft rejection
por: Böhmig, Georg A., et al.
Publicado: (2019)

Imagining a Better Outcome for Chronic Antibody-Mediated Rejection—Will Blocking Interleukin-6 Signaling Help?
por: Muthukumar, Thangamani, et al.
Publicado: (2022)

Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection
por: Waiser, Johannes, et al.
Publicado: (2016)

Late Cardiac Antibody-Mediated Rejection: A Only Heart Duel
por: Costa, Catarina, et al.
Publicado: (2022)

Non-invasive screening for sub-clinical antibody-mediated rejection as a new tool for indication of kidney allograft biopsy
por: Kozakowski, Nicolas
Publicado: (2019)

Belatacept Treatment of Recurrent Late-onset T Cell–mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient
por: Klintmalm, Göran B., et al.
Publicado: (2022)

Bortezomib: A New Promising Therapy for Early Antibody-Mediated Rejection After Liver Transplantation?
por: Chedid, Marcio F., et al.
Publicado: (2019)

How Do We Interpret the Presence of Donor-Specific Antibodies When There Is No Rejection?
por: Crew, R. John, et al.
Publicado: (2019)

The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
por: An, Gun Hee, et al.
Publicado: (2014)

AZD-1222/immune-globulin/rituximab: Coronary antibody-mediated rejection, thrombosis and lack of efficacy: case report
Publicado: (2022)

Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results
por: Mella, Alberto, et al.
Publicado: (2018)

Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia
por: Joachim, Emily, et al.
Publicado: (2020)

SLE - Rituximab in lupus
por: Eisenberg, Robert
Publicado: (2003)

Commentary: Rituximab in scleritis
por: Dutta Majumder, Parthopratim
Publicado: (2020)

Late and Chronic Antibody-Mediated Rejection: Main Barrier to Long Term Graft Survival
por: Sun, Qiquan, et al.
Publicado: (2013)

Fatal Pneumococcus Sepsis after Treatment of Late Antibody-Mediated Kidney Graft Rejection
por: Einecke, Gunilla, et al.
Publicado: (2018)

Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection
por: Mező, Blanka, et al.
Publicado: (2019)

Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?
por: Nourié, Nicole, et al.
Publicado: (2022)

Comparative Analysis of Determinants and Outcome of Early and Late Acute Antibody Mediated Rejection (ABMR)
por: Karthikeyan, Balasubramanian, et al.
Publicado: (2023)

Alpha E: No More Rejection?
por: Kilshaw, Peter J., et al.
Publicado: (2002)

Plasma cell-rich acute rejection: A morphologic archetype of combined cellular and humoral rejection?
por: Mubarak, M.
Publicado: (2016)

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
por: Eskandary, Farsad, et al.
Publicado: (2019)

Association Between Peripheral Blood CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients
por: Nanmoku, Koji, et al.
Publicado: (2019)

Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis
por: de Weerd, Annelies, et al.
Publicado: (2014)

Acute Antibody-mediated Rejection Coexisting With T Cell–mediated Rejection in Pediatric ABO-incompatible Transplantation
por: Yanagi, Yusuke, et al.
Publicado: (2022)

Updates on antibody-mediated rejection in intestinal transplantation
por: Wu, Guo-Sheng
Publicado: (2016)

Advances in diagnosing and managing antibody-mediated rejection
por: Jordan, Stanley C., et al.
Publicado: (2010)

Antibody-mediated rejection after lung transplantation
por: Bery, Amit I., et al.
Publicado: (2020)

GALLIUM trial: the tortoise (rituximab) and the hare (obinutuzumab) race
por: García-Muñoz, Ricardo, et al.
Publicado: (2019)

The Rejection Sensitivity Model: Sexual Minority Adolescents in Context
por: Baams, Laura, et al.
Publicado: (2019)

Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin
por: Ban, Tae Hyun, et al.
Publicado: (2021)

Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism
por: Mühlbacher, Jakob, et al.
Publicado: (2021)

Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
por: Lekpa, Fernando Kemta, et al.
Publicado: (2021)

Reconstitution of the adult B cell repertoire after treatment with rituximab
por: Sanz, Iñaki, et al.
Publicado: (2005)

The Role of Rituximab in Focal Segmental Glomerulosclerosis–Update From Italy
por: Gauckler, Philipp, et al.
Publicado: (2022)

Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
por: Eskandary, Farsad, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j54u487bcdbviat6jj8uijdlsm